^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BGI-9004

    i
    Other names: BGI-9004
    Associations

    News

    Trials
    Company:
    BridGene Biosci
    Drug class:
    TEAD inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential (AACR 2023)
    These results suggest that inhibition of YAP/TAZ-TEAD signaling may improve the efficacy of KRAS-targeted therapy. Taken together, the covalent TEAD inhibitor BGI-9004 has demonstrated promising activity both as a single agent and in combination with other targeted agents, a favorable pharmacokinetic profile and high target selectivity in preclinical models, supporting its evaluation as a novel anti-cancer agent in clinical trials.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • NF2 (Neurofibromin 2) • TEAD1 (TEA Domain Transcription Factor 1)
    |
    KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12D • NF2 mutation
    |
    BGI-9004 • Undisclosed YAP/TAZ-TEAD inhibitor